GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial.

Robert Dobbins,Robert Byerly,Riley Gaddy,Feng Gao,Kelly Mahar,Antonella Napolitano,Philip Ambery,Anne-Charlotte Le Monnier de Gouville

European Journal of Pharmacology（2015）

引用 14|浏览1

暂无评分

摘要

This study investigated safety and efficacy of GSK256073, an in vitro potent, selective GPR109A agonist, for treatment of subjects with type 2 diabetes mellitus (Type 2 DM) poorly controlled with metformin alone.

查看译文

关键词

GSK 256073 (PubChem CID 46215799)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要